WO2004000316A1 - Use of mglur5 antagonists for the treatment of gerd - Google Patents

Use of mglur5 antagonists for the treatment of gerd Download PDF

Info

Publication number
WO2004000316A1
WO2004000316A1 PCT/US2003/016223 US0316223W WO2004000316A1 WO 2004000316 A1 WO2004000316 A1 WO 2004000316A1 US 0316223 W US0316223 W US 0316223W WO 2004000316 A1 WO2004000316 A1 WO 2004000316A1
Authority
WO
WIPO (PCT)
Prior art keywords
antagonist
glutamate receptor
metabotropic glutamate
treatment
prevention
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2003/016223
Other languages
French (fr)
Inventor
Anders Lehmann
Jan Mattsson
Thomas M. Stormann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Shire NPS Pharmaceuticals Inc
Original Assignee
AstraZeneca AB
NPS Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20288301&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2004000316(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to UA20041210177A priority Critical patent/UA81627C2/en
Priority to US10/517,869 priority patent/US7964609B2/en
Priority to EP03731333A priority patent/EP1513525B1/en
Priority to DE60320990T priority patent/DE60320990D1/en
Priority to NZ536559A priority patent/NZ536559A/en
Priority to SI200331220T priority patent/SI1513525T1/en
Priority to DK03731333T priority patent/DK1513525T3/en
Priority to ES03731333T priority patent/ES2304510T3/en
Priority to CA2489730A priority patent/CA2489730C/en
Application filed by AstraZeneca AB, NPS Pharmaceuticals Inc filed Critical AstraZeneca AB
Priority to AU2003241585A priority patent/AU2003241585B2/en
Priority to BR0311759-6A priority patent/BR0311759A/en
Priority to JP2004515703A priority patent/JP4683920B2/en
Priority to HK05107987.5A priority patent/HK1075833B/en
Priority to MXPA04012659A priority patent/MXPA04012659A/en
Publication of WO2004000316A1 publication Critical patent/WO2004000316A1/en
Priority to IL16513804A priority patent/IL165138A0/en
Anticipated expiration legal-status Critical
Priority to NO20050154A priority patent/NO20050154L/en
Priority to IS7654A priority patent/IS7654A/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention relates to the use of metabotropic glutamate receptor 5 (mGluR5) antagonists for the inhibition of transient lower esophageal sphincter relaxations.
  • mGluR5 metabotropic glutamate receptor 5
  • a further aspect of the invention is directed to the use of metabotropic glutamate receptor 5 antagonists for the treatment of gastro-esophageal reflux disease, as well as for the treatment of regurgitation.
  • mGluR metabotropic glutamate receptors
  • CNS central nervous system
  • Eight metabotropic glutamate receptor subtypes have been identified and are subdivided into three groups based on sequence similarity.
  • Group I consists of mGluRl and mGluR5. These receptors activate phospholipase C and increase neuronal excitability.
  • Group LT consisting of mGluR2 and mGluR3 as well as group III, consisting of mGluR4, mGluR ⁇ , mGluR7 and mGluR8 are capable of inhibiting adenylyl cyclase activity and reduce synaptic transmission.
  • the lower esophageal sphincter (LES) is prone to relaxing intermittently. As a consequence, fluid from the stomach can pass into the esophagus since the mechanical barrier is temporarily lost at such times, an event hereinafter referred to as "reflux".
  • Gastro-esophageal reflux disease is the most prevalent upper gastrointestinal tract disease. Current pharmacotherapy aims at reducing gastric acid secretion, or at neutralizing acid in the esophagus. The major mechanism behind reflux has been considered to depend on a hypotonic lower esophageal sphincter. However, e.g. Holloway & Dent (1990) Gastroenterol. Clin. N. Amer. 19, pp. 517-535, has shown that most reflux episodes occur during transient lower esophageal sphincter relaxations (TLESRs), i.e. relaxations not triggered by swallows. It has also been shown that gastric acid secretion usually is normal in patients with GERD.
  • TLESRs transient lower esophageal sphincter relaxations
  • metabotropic glutamate receptors of group ⁇ and group III i.e. mGluR2, mGluR3, mGluR4, mGluR ⁇ , mGluR7 and mGluR8 may be involved in selective inhibitory modulation of peripheral mechanosensory endings.
  • the object of the present invention was to find a new way for the inhibition of transient lower esophageal sphincter relaxations (TLESRs), thereby preventing reflux. More particularly the object of the invention was to find a new and improved way of treating gastro-esophageal reflux disease (GERD), as well as a new and improved way for the treatment of regurgitation.
  • TLESRs transient lower esophageal sphincter relaxations
  • metabotropic glutamate receptor 5 (mGluR5) antagonists are useful for the inhibition of transient lower esophageal sphincter relaxations (TLESRs), and thus for the treatment of gastro-esophageal reflux disease (GERD).
  • TLESRs transient lower esophageal sphincter relaxations
  • GERD gastro-esophageal reflux disease
  • the present invention is directed to the use of a metabotropic glutamate receptor 5 antagonist for the manufacture of a medicament for the inhibition of transient lower esophageal sphincter relaxations (TLESRs).
  • TLESRs transient lower esophageal sphincter relaxations
  • GFD gastro-esophageal reflux disease
  • a further aspect of the invention is the use of a metabotropic glutamate receptor 5 antagonist for the manufacture of a medicament for the treatment of regurgitation.
  • Still a further aspect of the invention is the use of a metabotropic glutamate receptor 5 antagonist for the manufacture of a medicament for the treatment or prevention of lung disease.
  • Another aspect of the invention is the use of a metabotropic glutamate receptor 5 antagonist for the manufacture of a medicament for the management of failure to thrive.
  • Still a further aspect of the invention is the use of a metabotropic glutamate receptor 5 antagonist for the manufacture of a medicament for the treatment or prevention of asthma, such as reflux-related asthma.
  • Another aspect of the invention is the use of a metabotropic glutamate receptor 5 antagonist for the manufacture of a medicament for the treatment or prevention of chronic laryngitis.
  • a further aspect of the present invention is a method for the inhibition of transient lower esophageal sphincter relaxations (TLESRs), whereby a pharmaceutically and pharmacologically effective amount of a metabotropic glutamate receptor 5 antagonist is administered to a subject in need of such inhibition.
  • TLESRs transient lower esophageal sphincter relaxations
  • Another aspect of the invention is a method for the prevention of reflux, whereby a pharmaceutically and pharmacologically effective amount of a metabotropic glutamate receptor 5 antagonist is administered to a subject in need of such prevention.
  • Still a further aspect of the invention is a method for the treatment of gastro-esophageal reflux disease (GERD), whereby a pharmaceutically and pharmacologically effective amount of a metabotropic glutamate receptor 5 antagonist is administered to a subject in need of such treatment.
  • GSD gastro-esophageal reflux disease
  • Yet another aspect of the invention is a method for the treatment of regurgitation, whereby a pharmaceutically and pharmacologically effective amount of a metabotropic glutamate receptor 5 antagonist is administered to a subject in need of such treatment.
  • Still a further aspect of the invention is a method for the treatment or prevention of asthma, such as reflux-related asthma, whereby a pharmaceutically and pharmacologically effective amount of a metabotropic glutamate receptor 5 antagonist is administered to a subject in need of such treatment.
  • Still a further aspect of the invention is a method for the management of failure to thrive, whereby a pharmaceutically and pharmacologically effective amount of a metabotropic glutamate receptor 5 antagonist is administered to a subject in need of such treatment.
  • a pharmaceutically and pharmacologically effective amount of a metabotropic glutamate receptor 5 antagonist is administered to a subject in need of such treatment.
  • the term "antagonist” should be understood as including full antagonists, inverse agonists, non-competitive antagonists or competitive antagonists, as well as partial antagonists, whereby a "partial antagonist” should be understood as a compound capable of partially, but not fully, in-activating the metabotropic glutamate receptor 5.
  • TLESR transient lower esophageal sphincter relaxations
  • GFD gastro-esophageal reflux disease
  • MPEP 2- methyl-6-(phenylethynyl)-pyridine
  • MPEP is commercially available from e.g. Tocris, or may be synthesized according to well-known procedures such as disclosed by K. Sonogashira et al. in Tetrahedron Lett. (1975), 50, 4467-4470.
  • a further example of a compound having antagonistic affinity to metabotropic glutamate receptor 5, thereby being useful in accordance with the invention, is the compound 3-[3-(5- fluoropyridin-2-yl)-l,2,4-oxadiazol-5-yl]-5-(methoxymethyl)benzonitrile, having the structural formula:
  • salts of metabotropic glutamate receptor 5 antagonists are for example salts formed with mineral acids such as hydrochloric acid; alkali metal salts such as sodium or potassium salts; or alkaline earth metal salts such as calcium or magnesium salts.
  • Metabotropic glutamate receptor 5 antagonists having an asymmetric carbon atom are chiral compounds, and depending on the presence of asymmetric atoms, the metabotropic glutamate receptor 5 antagonists may exist in the form of mixtures of isomers, particularly racemates, or in the form of pure isomers such as specific enantiomers. The use of optical isomers of metabotropic glutamate receptor 5 antagonists is also within the scope of the present invention.
  • metabotropic glutamate receptor 5 antagonists are in accordance with the present invention suitably formulated into pharmaceutical formulations for oral administration. Also rectal, parenteral or any other route of administration may be contemplated to the skilled man in the art of formulations.
  • the metabotropic glutamate receptor 5 antagonists are formulated with at least one pharmaceutically and pharmacologically acceptable carrier or adjuvant.
  • the carrier may be in the form of a solid, semi-solid or liquid diluent.
  • the metabotropic glutamate receptor 5 antagonist(s) to be formulated is mixed with solid, powdered ingredients such as lactose, saccharose, sorbitol, mannitol, starch, amylopectin, cellulose derivatives, gelatin, or another suitable ingredient, as well as with disintegrating agents and lubricating agents such as magnesium stearate, calcium stearate, sodium stearyl fumarate and polyethylene glycol waxes.
  • disintegrating agents and lubricating agents such as magnesium stearate, calcium stearate, sodium stearyl fumarate and polyethylene glycol waxes.
  • Soft gelatine capsules may be prepared with capsules containing a mixture of the active compound or compounds of the invention, vegetable oil, fat, or other suitable vehicle for soft gelatine capsules.
  • Hard gelatine capsules may contain the active compound in combination with solid powdered ingredients such as lactose, saccharose, sorbitol, mannitol, potato starch, corn starch, amylopectin, cellulose derivatives or gelatine.
  • Dosage units for rectal administration may be prepared (i) in the form of suppositories which contain the active substance(s) mixed with a neutral fat base; (ii) in the form of a gelatine rectal capsule which contains the active substance in a mixture with a vegetable oil, paraffin oil, or other suitable vehicle for gelatine rectal capsules; (iii) in the form of a ready-made micro enema; or (iv) in the form of a dry micro enema formulation to be reconstituted in a suitable solvent just prior to administration.
  • Liquid preparations for oral administration may be prepared in the form of syrups or suspensions, e.g.
  • liquid preparations containing the active compound and the remainder of the formulation consisting of sugar or sugar alcohols, and a mixture of ethanol, water, glycerol, propylene glycol and polyethylene glycol.
  • liquid preparations may contain colouring agents, flavouring agents, saccharine and carboxymethyl cellulose or other thickening agent.
  • Liquid preparations for oral administration may also be prepared in the form of a dry powder to be reconstituted with a suitable solvent prior to use.
  • Solutions for parenteral administration may be prepared as a solution of a compound of the invention in a pharmaceutically acceptable solvent. These solutions may also contain stabilizing ingredients and/or buffering ingredients and are dispensed into unit doses in the form of ampoules or vials. Solutions for parenteral administration may also be prepared as a dry preparation to be reconstituted with a suitable solvent extemporaneously before use.
  • the metabotropic glutamate receptor 5 antagonists may be administered once or twice daily, depending on the severity of the patient's condition.
  • a typical daily dose of the metabotropic glutamate receptor 5 antagonists is from 0.1 - 100 mg per kg body weight of the subject to be treated, but this will depend on various factors such as the route of administration, the age and weight of the patient as well as of severity of the patient's condition.
  • Biological evaluation is from 0.1 - 100 mg per kg body weight of the subject to be treated, but this will depend on various factors such as the route of administration, the age and weight of the patient as well as of severity of the patient's condition.
  • a multilumen sleeVe/sidehole assembly (Dentsleeve, Sydney, South Australia) is introduced through the esophagostomy to measure gastric, lower esophageal sphincter (LES) and esophageal pressures.
  • the assembly is perfused with water using a low-compliance manometric perfusion pump (Dentsleeve, Sydney, South Australia).
  • An air-perfused tube is passed in the oral direction to measure swallows, and an antimony electrode monitored pH, 3 cm above the LES. All signals are amplified and acquired on a personal computer at 10 Hz.
  • placebo (0.9% NaCl) or test compound is administered intravenously (i.v., 0.5 ml/kg) in a foreleg vein.
  • a nutrient meal (10% peptone, 5% D-glucose, 5% Intralipid, pH 3.0) is infused into the stomach through the central lumen of the assembly at 100 ml/min to a final volume of 30 ml/kg.
  • air is insufflated at 40 ml/min.
  • TLESRs In an alternative model (Barostat model), the infusion of the nutrient meal is followed by air infusion at a rate of 500 ml/min until a intragastric pressure of lO ⁇ l mmHg is obtained. The pressure is then maintained at this level throughout the experiment using the infusion pump for further air infusion or for venting air from the stomach. The experimental time from start of nutrient infusion to end of air insufflation is 45 min. The procedure has been validated as a reliable means of triggering TLESRs. TLESRs is defined as a decrease in lower esophageal sphincter pressure (with reference to intragastric pressure) at a rate of >1 mmHg/s.
  • the relaxation should not be preceded by a pharyngeal signal ⁇ 2s before its onset in which case the relaxation is classified as swallow- induced.
  • the pressure difference between the LES and the stomach should be less than 2 mmHg, and the duration of the complete relaxation longer than 1 s.
  • 2-Methyl-6-(phenylethynyl)-pyridine was prepared according to the procedure described by K. Sonogashira et al. in Tetrahedron Lett. (1975), 50, 4467-4470. After purification by column chromatography (Si0 2 ), the hydrochloride salt (the hydrochloride salt of 2-methyl-6-(phenylethynyl)-pyridine is also commercially available from e.g. Tocris) was prepared by introducing HCl(g) to an ice-cooled Et 2 O-solution of the product. The hydrochloride salt of MPEP was tested on adult Labrador retrievers of both genders in accordance with the test model described above.
  • 3-fluoro-5-[3-(5-fluoropyridin-2-yl)-l,2,4-oxadiazol-5-yl]benzonitrile was prepared according to the procedure described in WO 01/12627. 3-fluoro-5-[3-(5-fluoropyridin-2- yl)-l,2,4-oxadiazol-5-yl]benzonitrile was tested on adult Labrador retrievers of both genders in accordance with the barostat model described above.

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Steroid Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

The present invention relates to the use of metabotropic glutamate receptor 5 antagonists for the inhibition of transient lower esophageal sphincter relaxations. A further aspects of the invention is directed to the use of metabotropic glutamate receptor 5 antagonists for the treatment of gastro, esophageal reflux disease, as well as for the treatment of regurgitation and asthma.

Description

USE OF MGLUR5 ANTAGONISTS FOR THE TREATMENT OF GERD
Field of the invention
The present invention relates to the use of metabotropic glutamate receptor 5 (mGluR5) antagonists for the inhibition of transient lower esophageal sphincter relaxations. A further aspect of the invention is directed to the use of metabotropic glutamate receptor 5 antagonists for the treatment of gastro-esophageal reflux disease, as well as for the treatment of regurgitation.
Background of the invention
The metabotropic glutamate receptors (mGluR) are G-protein coupled receptors that are involved in the regulation and activity of many synapses in the central nervous system (CNS). Eight metabotropic glutamate receptor subtypes have been identified and are subdivided into three groups based on sequence similarity. Group I consists of mGluRl and mGluR5. These receptors activate phospholipase C and increase neuronal excitability. Group LT, consisting of mGluR2 and mGluR3 as well as group III, consisting of mGluR4, mGluRό, mGluR7 and mGluR8 are capable of inhibiting adenylyl cyclase activity and reduce synaptic transmission. Several of the receptors also exist in various isoforms, occurring by alternative splicing (Chen, C-Yet al, Journal of Physiology (2002), 538.3, pp. 773-786; Pin, J-P et al, European Journal of Pharmacology (1999), 375, pp. 277-294; Brauner-Osborne, H et al. Journal of Medicinal Chemistry (2000), 43, pp. 2609-2645; Schoepp, D.D, Jane D.E. Monn J.A. Neuropharmacology (1999), 38, pp. 1431-1476).
The lower esophageal sphincter (LES) is prone to relaxing intermittently. As a consequence, fluid from the stomach can pass into the esophagus since the mechanical barrier is temporarily lost at such times, an event hereinafter referred to as "reflux".
Gastro-esophageal reflux disease (GERD) is the most prevalent upper gastrointestinal tract disease. Current pharmacotherapy aims at reducing gastric acid secretion, or at neutralizing acid in the esophagus. The major mechanism behind reflux has been considered to depend on a hypotonic lower esophageal sphincter. However, e.g. Holloway & Dent (1990) Gastroenterol. Clin. N. Amer. 19, pp. 517-535, has shown that most reflux episodes occur during transient lower esophageal sphincter relaxations (TLESRs), i.e. relaxations not triggered by swallows. It has also been shown that gastric acid secretion usually is normal in patients with GERD.
According to Blackshaw L.A. et al, presentation at the conference Neurogastroenterology & Motility, Madison, Wisconsin, 14 November 2001, metabotropic glutamate receptors of group π and group III, i.e. mGluR2, mGluR3, mGluR4, mGluRό, mGluR7 and mGluR8 may be involved in selective inhibitory modulation of peripheral mechanosensory endings.
The object of the present invention was to find a new way for the inhibition of transient lower esophageal sphincter relaxations (TLESRs), thereby preventing reflux. More particularly the object of the invention was to find a new and improved way of treating gastro-esophageal reflux disease (GERD), as well as a new and improved way for the treatment of regurgitation.
Outline of the invention
It has now surprisingly been found that metabotropic glutamate receptor 5 (mGluR5) antagonists are useful for the inhibition of transient lower esophageal sphincter relaxations (TLESRs), and thus for the treatment of gastro-esophageal reflux disease (GERD).
Consequently, the present invention is directed to the use of a metabotropic glutamate receptor 5 antagonist for the manufacture of a medicament for the inhibition of transient lower esophageal sphincter relaxations (TLESRs).
A further aspect of the invention is the use of a metabotropic glutamate receptor 5 antagonist for the manufacture of a medicament for the prevention of reflux. Still a further aspect of the invention is the use of a metabotropic glutamate receptor 5 antagonist for the manufacture of a medicament for the treatment of gastro-esophageal reflux disease (GERD).
Effective prevention of regurgitation would be an important way of preventing, as well as curing lung disease due to aspiration of regurgitated gastric contents, and for managing failure to thrive. Thus, a further aspect of the invention is the use of a metabotropic glutamate receptor 5 antagonist for the manufacture of a medicament for the treatment of regurgitation.
Still a further aspect of the invention is the use of a metabotropic glutamate receptor 5 antagonist for the manufacture of a medicament for the treatment or prevention of lung disease.
Another aspect of the invention is the use of a metabotropic glutamate receptor 5 antagonist for the manufacture of a medicament for the management of failure to thrive.
Still a further aspect of the invention is the use of a metabotropic glutamate receptor 5 antagonist for the manufacture of a medicament for the treatment or prevention of asthma, such as reflux-related asthma.
Another aspect of the invention is the use of a metabotropic glutamate receptor 5 antagonist for the manufacture of a medicament for the treatment or prevention of chronic laryngitis.
A further aspect of the present invention is a method for the inhibition of transient lower esophageal sphincter relaxations (TLESRs), whereby a pharmaceutically and pharmacologically effective amount of a metabotropic glutamate receptor 5 antagonist is administered to a subject in need of such inhibition. Another aspect of the invention is a method for the prevention of reflux, whereby a pharmaceutically and pharmacologically effective amount of a metabotropic glutamate receptor 5 antagonist is administered to a subject in need of such prevention.
Still a further aspect of the invention is a method for the treatment of gastro-esophageal reflux disease (GERD), whereby a pharmaceutically and pharmacologically effective amount of a metabotropic glutamate receptor 5 antagonist is administered to a subject in need of such treatment.
Yet another aspect of the invention is a method for the treatment of regurgitation, whereby a pharmaceutically and pharmacologically effective amount of a metabotropic glutamate receptor 5 antagonist is administered to a subject in need of such treatment.
Still a further aspect of the invention is a method for the treatment or prevention of asthma, such as reflux-related asthma, whereby a pharmaceutically and pharmacologically effective amount of a metabotropic glutamate receptor 5 antagonist is administered to a subject in need of such treatment.
Yet another aspect of the invention is a method for the treatment of chronic laryngitis, whereby a pharmaceutically and pharmacologically effective amount of a metabotropic glutamate receptor 5 antagonist is administered to a subject in need of such treatment. Still a further aspect of the invention is a method for the treatment or inhibition of lung disease, whereby a pharmaceutically and pharmacologically effective amount of a metabotropic glutamate receptor 5 antagonist is administered to a subject in need of such treatment.
Still a further aspect of the invention is a method for the management of failure to thrive, whereby a pharmaceutically and pharmacologically effective amount of a metabotropic glutamate receptor 5 antagonist is administered to a subject in need of such treatment. For the purpose of this invention, the term "antagonist" should be understood as including full antagonists, inverse agonists, non-competitive antagonists or competitive antagonists, as well as partial antagonists, whereby a "partial antagonist" should be understood as a compound capable of partially, but not fully, in-activating the metabotropic glutamate receptor 5.
The wording "TLESR", transient lower esophageal sphincter relaxations, is herein defined in accordance with Mittal, R.K., Holloway, R.H., Penagini, R., Blackshaw, L.A., Dent, J„ 1995; Transient lower esophageal sphincter relaxation. Gastroenterology 109, pp. 601-610.
The wording "reflux" is defined as fluid from the stomach being able to pass into the esophagus, since the mechanical barrier is temporarily lost at such times.
The wording "GERD", gastro-esophageal reflux disease, is defined in accordance with van Heerwarden, M.A., Smout A.J.P.M., 2000; Diagnosis of reflux disease. Bailliere's Clin. Gastroenterol. 14, pp. 759-774.
One example of a compound having antagonistic affinity to metabotropic glutamate receptor 5, thereby being useful in accordance with the invention, is the compound 2- methyl-6-(phenylethynyl)-pyridine (often abbreviated MPEP). MPEP is commercially available from e.g. Tocris, or may be synthesized according to well-known procedures such as disclosed by K. Sonogashira et al. in Tetrahedron Lett. (1975), 50, 4467-4470.
A further example of a compound having antagonistic affinity to metabotropic glutamate receptor 5, thereby being useful in accordance with the invention, is the compound 3-[3-(5- fluoropyridin-2-yl)-l,2,4-oxadiazol-5-yl]-5-(methoxymethyl)benzonitrile, having the structural formula:
Figure imgf000007_0001
Yet another example of a compound having antagonistic affinity to metabotropic glutamate receptor 5, thereby being useful in accordance with the invention, is the compound 3- fluoro-5-[3-(5-fluoropyridin-2-yl)-l,2,4-oxadiazol-5-yl]benzonitrile, having the structural formula:
Figure imgf000007_0002
The use of pharmaceutically acceptable salts of metabotropic glutamate receptor 5 antagonists is also within the scope of the present invention. Such salts are for example salts formed with mineral acids such as hydrochloric acid; alkali metal salts such as sodium or potassium salts; or alkaline earth metal salts such as calcium or magnesium salts.
Metabotropic glutamate receptor 5 antagonists having an asymmetric carbon atom are chiral compounds, and depending on the presence of asymmetric atoms, the metabotropic glutamate receptor 5 antagonists may exist in the form of mixtures of isomers, particularly racemates, or in the form of pure isomers such as specific enantiomers. The use of optical isomers of metabotropic glutamate receptor 5 antagonists is also within the scope of the present invention. Pharmaceutical formulations
For clinical use, the metabotropic glutamate receptor 5 antagonists are in accordance with the present invention suitably formulated into pharmaceutical formulations for oral administration. Also rectal, parenteral or any other route of administration may be contemplated to the skilled man in the art of formulations. Thus, the metabotropic glutamate receptor 5 antagonists are formulated with at least one pharmaceutically and pharmacologically acceptable carrier or adjuvant. The carrier may be in the form of a solid, semi-solid or liquid diluent.
In the preparation of oral pharmaceutical formulations in accordance with the invention, the metabotropic glutamate receptor 5 antagonist(s) to be formulated is mixed with solid, powdered ingredients such as lactose, saccharose, sorbitol, mannitol, starch, amylopectin, cellulose derivatives, gelatin, or another suitable ingredient, as well as with disintegrating agents and lubricating agents such as magnesium stearate, calcium stearate, sodium stearyl fumarate and polyethylene glycol waxes. The mixture is then processed into granules or compressed into tablets.
Soft gelatine capsules may be prepared with capsules containing a mixture of the active compound or compounds of the invention, vegetable oil, fat, or other suitable vehicle for soft gelatine capsules. Hard gelatine capsules may contain the active compound in combination with solid powdered ingredients such as lactose, saccharose, sorbitol, mannitol, potato starch, corn starch, amylopectin, cellulose derivatives or gelatine.
Dosage units for rectal administration may be prepared (i) in the form of suppositories which contain the active substance(s) mixed with a neutral fat base; (ii) in the form of a gelatine rectal capsule which contains the active substance in a mixture with a vegetable oil, paraffin oil, or other suitable vehicle for gelatine rectal capsules; (iii) in the form of a ready-made micro enema; or (iv) in the form of a dry micro enema formulation to be reconstituted in a suitable solvent just prior to administration. Liquid preparations for oral administration may be prepared in the form of syrups or suspensions, e.g. solutions or suspensions, containing the active compound and the remainder of the formulation consisting of sugar or sugar alcohols, and a mixture of ethanol, water, glycerol, propylene glycol and polyethylene glycol. If desired, such liquid preparations may contain colouring agents, flavouring agents, saccharine and carboxymethyl cellulose or other thickening agent. Liquid preparations for oral administration may also be prepared in the form of a dry powder to be reconstituted with a suitable solvent prior to use.
Solutions for parenteral administration may be prepared as a solution of a compound of the invention in a pharmaceutically acceptable solvent. These solutions may also contain stabilizing ingredients and/or buffering ingredients and are dispensed into unit doses in the form of ampoules or vials. Solutions for parenteral administration may also be prepared as a dry preparation to be reconstituted with a suitable solvent extemporaneously before use.
In one aspect of the present invention, the metabotropic glutamate receptor 5 antagonists may be administered once or twice daily, depending on the severity of the patient's condition.
A typical daily dose of the metabotropic glutamate receptor 5 antagonists is from 0.1 - 100 mg per kg body weight of the subject to be treated, but this will depend on various factors such as the route of administration, the age and weight of the patient as well as of severity of the patient's condition. Biological evaluation
Screening for compounds active against TLESR
Adult Labrador retrievers of both genders, trained to stand in a Pavlov sling, are used. Mucosa-to-skin esophagostomies are formed and the dogs are allowed to recover completely before any experiments are done.
Motility measurement
In brief, after fasting for approximately 17 h with free supply of water, a multilumen sleeVe/sidehole assembly (Dentsleeve, Adelaide, South Australia) is introduced through the esophagostomy to measure gastric, lower esophageal sphincter (LES) and esophageal pressures. The assembly is perfused with water using a low-compliance manometric perfusion pump (Dentsleeve, Adelaide, South Australia). An air-perfused tube is passed in the oral direction to measure swallows, and an antimony electrode monitored pH, 3 cm above the LES. All signals are amplified and acquired on a personal computer at 10 Hz.
When a baseline measurement free from fasting gastric LES phase HI motor activity has been obtained, placebo (0.9% NaCl) or test compound is administered intravenously (i.v., 0.5 ml/kg) in a foreleg vein. Ten min after i.v. administration, a nutrient meal (10% peptone, 5% D-glucose, 5% Intralipid, pH 3.0) is infused into the stomach through the central lumen of the assembly at 100 ml/min to a final volume of 30 ml/kg. Immediately following the meal, air is insufflated at 40 ml/min. In an alternative model (Barostat model), the infusion of the nutrient meal is followed by air infusion at a rate of 500 ml/min until a intragastric pressure of lO±l mmHg is obtained. The pressure is then maintained at this level throughout the experiment using the infusion pump for further air infusion or for venting air from the stomach. The experimental time from start of nutrient infusion to end of air insufflation is 45 min. The procedure has been validated as a reliable means of triggering TLESRs. TLESRs is defined as a decrease in lower esophageal sphincter pressure (with reference to intragastric pressure) at a rate of >1 mmHg/s. The relaxation should not be preceded by a pharyngeal signal <2s before its onset in which case the relaxation is classified as swallow- induced. The pressure difference between the LES and the stomach should be less than 2 mmHg, and the duration of the complete relaxation longer than 1 s.
EXAMPLES
Example 1
2-Methyl-6-(phenylethynyl)-pyridine (MPEP) was prepared according to the procedure described by K. Sonogashira et al. in Tetrahedron Lett. (1975), 50, 4467-4470. After purification by column chromatography (Si02), the hydrochloride salt (the hydrochloride salt of 2-methyl-6-(phenylethynyl)-pyridine is also commercially available from e.g. Tocris) was prepared by introducing HCl(g) to an ice-cooled Et2O-solution of the product. The hydrochloride salt of MPEP was tested on adult Labrador retrievers of both genders in accordance with the test model described above.
Inhibition of the number of TLESRs was calculated with regard to the five preceding control experiments for each dog, and the results as set out in Tables 1.1 and 1.2 below were achieved.
Table 1.1 - Standard model
Figure imgf000012_0001
N = number of dogs tested SEM = standard error of mean
Table 1.2 - Standard model
Figure imgf000012_0002
N = number of dogs tested SEM = standard error of mean EXAMPLE 2
3-[3-(5-fluoropyridin-2-yl)-l,2,4-oxadiazol-5-yl]-5-(methoxymethyl)benzonitrile was prepared according to the procedure described in WO 02/068417. 3-[3-(5-fluoropyridin-2- yl)-l,2,4-oxadiazol-5-yl]-5-(methoxymethyl)benzonitrile was tested on adult Labrador retrievers of both genders in accordance with the barostat model described above.
Table 2.1 - Barostat model
Figure imgf000013_0001
N = number of dogs tested SEM = standard error of mean
EXAMPLE 3
3-fluoro-5-[3-(5-fluoropyridin-2-yl)-l,2,4-oxadiazol-5-yl]benzonitrile was prepared according to the procedure described in WO 01/12627. 3-fluoro-5-[3-(5-fluoropyridin-2- yl)-l,2,4-oxadiazol-5-yl]benzonitrile was tested on adult Labrador retrievers of both genders in accordance with the barostat model described above.
Table 3.1 - Barostat model
Figure imgf000014_0001
N = number of dogs tested SEM = standard error of mean
The results shown in the Examples above, support that metabotropic glutamate receptor 5 antagonists are useful for the inhibition of TLESRs, and thus for the treatment of GERD.

Claims

Claims
1. Use of a metabotropic glutamate receptor 5 antagonist, or a pharmaceutically acceptable salt or an optical isomer thereof, for the manufacture of a medicament for the inhibition of transient lower esophageal sphincter relaxations (TLESRs).
2. Use of a metabotropic glutamate receptor 5 antagonist, or a pharmaceutically acceptable salt or an optical isomer thereof, for the manufacture of a medicament for the treatment of gastro-esophageal reflux disease (GERD).
3. Use of a metabotropic glutamate receptor 5 antagonist, or a pharmaceutically acceptable salt or an optical isomer thereof, for the manufacture of a medicament for the prevention of reflux.
4. Use of a metabotropic glutamate receptor 5 antagonist, or a pharmaceutically acceptable salt or an optical isomer thereof, for the manufacture of a medicament for the treatment of, or prevention of, regurgitation.
5. Use of a metabotropic glutamate receptor 5 antagonist, or a pharmaceutically acceptable salt or an optical isomer thereof, for the manufacture of a medicament for the treatment of, or prevention of, asthma.
6. Use according to claim 5, wherein the asthma is reflux-related asthma.
7. Use of a metabotropic glutamate receptor 5 antagonist, or a pharmaceutically acceptable salt or an optical isomer thereof, for the manufacture of a medicament for the treatment of, or prevention of, chronic laryngitis.
8. Use of a metabotropic glutamate receptor 5 antagonist, or a pharmaceutically acceptable salt or an optical isomer thereof, for the manufacture of a medicament for the treatment of, or prevention of, lung disease.
9. Use of a metabotropic glutamate receptor 5 antagonist, or a pharmaceutically acceptable salt or an optical isomer thereof, for the manufacture of a medicament for managing failure to thrive.
10. Use according to any one of the preceding claims, wherein the metabotropic glutamate receptor 5 antagonist is 2-methyl-6-(phenylefhynyl)-pyridine.
11. Use according to claim 10, wherein the metabotropic glutamate receptor 5 antagonist is the hydrochloride salt of 2-methyl-6-(phenylethynyl)-pyridine.
12. Use according to any one of claims 1-9, wherein the metabotropic glutamate receptor antagonist is 3-[3-(5-fluoropyridin-2-yl)-l,2,4-oxadiazol-5-yi]-5- (methoxyrnefhyl)benzonitrile.
13. Use according to any one of claims 1-9, wherein the metabotropic glutamate receptor antagonist is 3-fluoro-5- [3-(5-fluoropyridin-2-yl)- 1 ,2,4-oxadiazol-5- yljbenzonitrile.
14. Use according to any one of the preceding claims, wherein the daily dose of the metabotropic glutamate receptor 5 antagonist is from 0.1 - 100 mg per kg body weight of the subject to be treated.
15. A method for the inhibition of transient lower esophageal sphincter relaxations (TLESRs), whereby a pharmaceutically and pharmacologically effective amount of a metabotropic glutamate receptor 5 antagonist, or a pharmaceutically acceptable salt or an optical isomer thereof, is administered to a subject in need of such inhibition.
16. A method for the treatment of gastro-esophageal reflux disease (GERD), whereby a pharmaceutically and pharmacologically effective amount of a metabotropic glutamate receptor 5 antagonist, or a pharmaceutically acceptable salt or an optical isomer thereof, is administered to a subject in need of such treatment.
17. A method for the prevention of reflux, whereby a pharmaceutically and pharmacologically effective amount of a metabotropic glutamate receptor 5 antagonist, or a pharmaceutically acceptable salt or an optical isomer thereof, is administered to a subject in need of such prevention.
18. A method for the treatment of, or prevention of, regurgitation, whereby a pharmaceutically and pharmacologically effective amount of a metabotropic glutamate receptor 5 antagonist, or a pharmaceutically acceptable salt or an optical isomer thereof, is administered to a subject in need of such treatment or prevention.
19. A method for the prevention of, or treatment of, lung disease, whereby a pharmaceutically and pharmacologically effective amount of a metabotropic glutamate receptor 5 antagonist, or a pharmaceutically acceptable salt or an optical isomer thereof, is administered to a subject in need of such treatment or prevention.
20. A method for managing failure to thrive, whereby a pharmaceutically and pharmacologically effective amount of a metabotropic glutamate receptor 5 antagonist, or a pharmaceutically acceptable salt or an optical isomer thereof, is administered to a subject in need of such management.
21. A method for treatment or prevention of asthma, whereby a pharmaceutipally and pharmacologically effective amount of a metabotropic glutamate receptor 5 antagonist, or a pharmaceutically acceptable salt or an optical isomer thereof, is administered to a subject in need of such treatment or prevention.
22. A method according to claim 21, wherein the asthma is reflux-related asthma.
23. A method for treatment or prevention of chronic laryngitis, whereby a pharmaceutically and pharmacologically effective amount of a metabotropic glutamate receptor 5 antagonist, or a pharmaceutically acceptable salt or an optical isomer thereof, is administered to a subject in need of such treatment or prevention.
24. A method according to any one of claims 15-23, wherein the metabotropic glutamate receptor 5 antagonist is 2-methyl-6-(phenylethynyl)-pyridine.
25. A method according to claim 24, wherein the metabotropic glutamate receptor 5 antagonist is the hydrochloride salt of 2-methyl-6-(phenylethynyl)-pyridine.
26. A method according to any one of claims 15-23, wherein the metabotropic glutamate receptor 5 antagonist is 3-[3-(5-fluoropyridin-2-yl)-l,2,4-oxadiazol-5- yl]-5-(methoxymethyl)benzonitrile.
27. A method according to any one of claims 15-23, wherein the metabotropic glutamate receptor 5 antagonist is 3-fluoro-5-[3-(5-fluoropyridin-2-yl)-l,2,4- oxadiazol-5-yl]benzonitrile.
28. A method according to any one of claims 15-27, wherein the daily dose of the metabotropic glutamate receptor 5 antagonist is from 0.1 - 100 mg per kg body weight of the subject to be treated.
PCT/US2003/016223 2002-06-20 2003-06-19 Use of mglur5 antagonists for the treatment of gerd Ceased WO2004000316A1 (en)

Priority Applications (17)

Application Number Priority Date Filing Date Title
MXPA04012659A MXPA04012659A (en) 2002-06-20 2003-06-19 Use of mglur5 antagonists for the treatment of gerd.
AU2003241585A AU2003241585B2 (en) 2002-06-20 2003-06-19 Use of mGluR5 antagonists for the treatment of GERD
EP03731333A EP1513525B1 (en) 2002-06-20 2003-06-19 Use of mglur5 antagonists for the treatment of gerd
DE60320990T DE60320990D1 (en) 2002-06-20 2003-06-19 USE OF MGLUR5 ANTAGONISTS FOR THE TREATMENT OF GASTROESOPHAGAL REFLUXES
NZ536559A NZ536559A (en) 2002-06-20 2003-06-19 Use of a metabotropic glutamate receptor 5 antagonist for the treatment of gastro-esphageal reflux disease
SI200331220T SI1513525T1 (en) 2002-06-20 2003-06-19 Use of mglur5 antagonists for the treatment of gerd
DK03731333T DK1513525T3 (en) 2002-06-20 2003-06-19 Use of MGLUR5 antagonists in the treatment of GERD
ES03731333T ES2304510T3 (en) 2002-06-20 2003-06-19 USE OF MGLUR5 ANTAGONISTS FOR THE TREATMENT OF GERD.
CA2489730A CA2489730C (en) 2002-06-20 2003-06-19 Use of mglur5 antagonists for the treatment of gerd
UA20041210177A UA81627C2 (en) 2002-06-20 2003-06-19 Use of mglur5 antagonists for the treatment of esophageal reflux disease
JP2004515703A JP4683920B2 (en) 2002-06-20 2003-06-19 Use of MGLUR5 antagonists for the treatment of GERD
US10/517,869 US7964609B2 (en) 2002-06-20 2003-06-19 Use of mGluR5 antagonists for the treatment of gerd
BR0311759-6A BR0311759A (en) 2002-06-20 2003-06-19 Uses of a metabotropic glutamate receptor 5 antagonist or a pharmaceutically acceptable salt or optical isomer thereof and methods of inhibiting transient lower esophageal sphincter relaxation, treating gastro-oesophageal reflux disease, preventing reflux, treating or prevention of regurgitation, lung disease, asthma, chronic laryngitis and management of poor development
HK05107987.5A HK1075833B (en) 2002-06-20 2003-06-19 Use of mglur5 antagonists for the treatment of gerd
IL16513804A IL165138A0 (en) 2002-06-20 2004-11-10 Use of mglur5 antagonists for the treatment of gerd
NO20050154A NO20050154L (en) 2002-06-20 2005-01-11 Use of MGLUR5 antagonists in the treatment of GERD
IS7654A IS7654A (en) 2002-06-20 2005-01-19 Use of MGLUR5 antagonists for the treatment of gastro-oesophageal reflux disease

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0201943-8 2002-06-20
SE0201943A SE0201943D0 (en) 2002-06-20 2002-06-20 New use

Publications (1)

Publication Number Publication Date
WO2004000316A1 true WO2004000316A1 (en) 2003-12-31

Family

ID=20288301

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/016223 Ceased WO2004000316A1 (en) 2002-06-20 2003-06-19 Use of mglur5 antagonists for the treatment of gerd

Country Status (24)

Country Link
EP (1) EP1513525B1 (en)
JP (2) JP4683920B2 (en)
CN (1) CN100430056C (en)
AT (1) ATE395059T1 (en)
AU (1) AU2003241585B2 (en)
BR (1) BR0311759A (en)
CA (1) CA2489730C (en)
CY (1) CY1107954T1 (en)
DE (1) DE60320990D1 (en)
DK (1) DK1513525T3 (en)
ES (1) ES2304510T3 (en)
IL (1) IL165138A0 (en)
IS (1) IS7654A (en)
MX (1) MXPA04012659A (en)
NO (1) NO20050154L (en)
NZ (1) NZ536559A (en)
PL (1) PL372186A1 (en)
PT (1) PT1513525E (en)
RU (1) RU2324484C2 (en)
SE (1) SE0201943D0 (en)
SI (1) SI1513525T1 (en)
UA (1) UA81627C2 (en)
WO (1) WO2004000316A1 (en)
ZA (1) ZA200409908B (en)

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005060971A1 (en) * 2003-12-18 2005-07-07 Astrazeneca Ab Treatment of reflux-related diseases
WO2005060965A1 (en) * 2003-12-17 2005-07-07 Astrazeneca Ab Novel treatment of irritable bowel syndrome i
WO2005077345A1 (en) * 2004-02-03 2005-08-25 Astrazeneca Ab Compounds for the treatment of gastro-esophageal reflux disease
WO2005080363A1 (en) * 2004-02-18 2005-09-01 Astrazeneca Ab Acetylinic piperazine compounds and their use as metabotropic glutamate receptor antagonists
WO2005077368A3 (en) * 2004-02-03 2005-11-24 Astrazeneca Ab Treatment of gastro-esophageal reflux disease (gerd)
WO2005060961A3 (en) * 2003-12-18 2006-01-05 Astrazeneca Ab Treatment of transient lower esophageal sphincter relaxations (tlesrs) and gastro-esophageal reflux disease (gerd)
WO2007006530A1 (en) * 2005-07-12 2007-01-18 Novartis Ag Use of mglur5 (esp. afq056) in gi (esp. gerd)
WO2009024491A1 (en) * 2007-08-20 2009-02-26 F. Hoffmann-La Roche Ag Use of mglur5 antagonists for the treatment of gerd
EP2272509A1 (en) 2006-09-11 2011-01-12 Novartis AG New Uses of metabotropic glutamate receptors
WO2011009890A2 (en) 2009-07-23 2011-01-27 Novartis Ag Use of azabicycloalkyl derivatives or pyrrolidine-2-one derivatives
WO2011036167A1 (en) 2009-09-22 2011-03-31 Novartis Ag Use of nicotinic acetylcholine receptor alpha 7 activators
WO2011048150A1 (en) 2009-10-20 2011-04-28 Novartis Ag Use of 1h-quinazoline-2,4-diones
WO2011161249A1 (en) 2010-06-24 2011-12-29 Novartis Ag Use of 1h-quinazoline-2,4-diones
WO2012101060A1 (en) 2011-01-27 2012-08-02 Novartis Ag Use of nicotinic acetylcholine receptor alpha 7 activators
WO2013036224A1 (en) 2011-09-07 2013-03-14 Novartis Ag Use of 1h-quinazoline- 2, 4 -diones for use in the prevention or treatment photosensitive epilepsy
WO2014111751A1 (en) 2013-01-15 2014-07-24 Novartis Ag Use of alpha 7 nicotinic receptor agonists for the treatment of narcolepsy
WO2014111837A1 (en) 2013-01-15 2014-07-24 Novartis Ag Use of alpha 7 nicotinic acetylcholine receptor agonists
EP2826478A1 (en) 2008-06-30 2015-01-21 Novartis AG Combinations comprising mglur modulators for the treatment of parkinson's disease
US20220387410A1 (en) * 2019-11-05 2022-12-08 Claes Thulin 4-[5-[(rac)-1-[5-(3-Chlorophenyl)-3-isoxazolyl]ethoxy]-4-methyl-4H-1,2,4-triazol-3-yl]pyridine for use in prevention and/or treatment of surmenage in a mammal

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7964609B2 (en) 2002-06-20 2011-06-21 Astrazeneca Ab Use of mGluR5 antagonists for the treatment of gerd
US20070185100A1 (en) * 2004-02-18 2007-08-09 Astrazeneca Ab Poly-heterocyclic compounds and their use as metabotropic glutamate receptor antagonists
WO2007110337A1 (en) * 2006-03-29 2007-10-04 F. Hoffmann-La Roche Ag Pyridine and pyrimidine derivatives as mglur2 antagonists
JP2008245225A (en) * 2007-03-29 2008-10-09 Kddi Corp Wavelength path determination device, wavelength path setting control system, and program

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5036057A (en) * 1986-01-03 1991-07-30 The University Of Melbourne Method of treating gastroesophageal reflux
WO1999059612A1 (en) * 1998-05-15 1999-11-25 Aphton Corporation Method for the treatment of gastroesophageal reflux disease
US6117908A (en) * 1996-09-18 2000-09-12 Astra Aktiebolag Use of GABAB receptor agonists as reflux inhibitors
WO2001012627A1 (en) * 1999-08-19 2001-02-22 Nps Pharmaceuticals, Inc. Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2144331C1 (en) * 1998-11-05 2000-01-20 Московский НИИ уха, горла и носа Method of chronic hyperplastic laryngitis treatment
CZ20031145A3 (en) * 2000-10-02 2003-12-17 Janssen Pharmaceutica N.V. Antagonists of metabotropic glutamate receptor

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5036057A (en) * 1986-01-03 1991-07-30 The University Of Melbourne Method of treating gastroesophageal reflux
US6117908A (en) * 1996-09-18 2000-09-12 Astra Aktiebolag Use of GABAB receptor agonists as reflux inhibitors
WO1999059612A1 (en) * 1998-05-15 1999-11-25 Aphton Corporation Method for the treatment of gastroesophageal reflux disease
WO2001012627A1 (en) * 1999-08-19 2001-02-22 Nps Pharmaceuticals, Inc. Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GASPARINI F ET AL: "2-METHYL-6-(PHENYLETHYNYL)-PYRIDINE (MPEP), A POTENT, SELECTIVE ANDSYSTEMICALLY ACTIVE MGLU5 RECEPTOR ANTAGONIST", NEUROPHARMACOLOGY, PERGAMON PRESS, OXFORD, GB, vol. 38, no. 10, October 1999 (1999-10-01), pages 1493 - 1503, XP001032948, ISSN: 0028-3908 *
KNÖPFEL T ET AL: "Metabotropic Glutamate Receptors: Novel targets for drug development", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 38, no. 9, 28 April 1995 (1995-04-28), pages 1417 - 1426, XP000611483, ISSN: 0022-2623 *

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005060965A1 (en) * 2003-12-17 2005-07-07 Astrazeneca Ab Novel treatment of irritable bowel syndrome i
WO2005060961A3 (en) * 2003-12-18 2006-01-05 Astrazeneca Ab Treatment of transient lower esophageal sphincter relaxations (tlesrs) and gastro-esophageal reflux disease (gerd)
WO2005060971A1 (en) * 2003-12-18 2005-07-07 Astrazeneca Ab Treatment of reflux-related diseases
WO2005077345A1 (en) * 2004-02-03 2005-08-25 Astrazeneca Ab Compounds for the treatment of gastro-esophageal reflux disease
WO2005077368A3 (en) * 2004-02-03 2005-11-24 Astrazeneca Ab Treatment of gastro-esophageal reflux disease (gerd)
WO2005080363A1 (en) * 2004-02-18 2005-09-01 Astrazeneca Ab Acetylinic piperazine compounds and their use as metabotropic glutamate receptor antagonists
AU2006268905B2 (en) * 2005-07-12 2010-01-21 Novartis Ag Use of mGluR5 (esp. AFQ056) in GI (esp. GERD)
WO2007006530A1 (en) * 2005-07-12 2007-01-18 Novartis Ag Use of mglur5 (esp. afq056) in gi (esp. gerd)
JP2009501171A (en) * 2005-07-12 2009-01-15 ノバルティス アクチエンゲゼルシャフト Use of mGluR5 (especially AFQ056) in GI (especially GERD)
EP2272509A1 (en) 2006-09-11 2011-01-12 Novartis AG New Uses of metabotropic glutamate receptors
WO2009024491A1 (en) * 2007-08-20 2009-02-26 F. Hoffmann-La Roche Ag Use of mglur5 antagonists for the treatment of gerd
EP2826478A1 (en) 2008-06-30 2015-01-21 Novartis AG Combinations comprising mglur modulators for the treatment of parkinson's disease
WO2011009890A2 (en) 2009-07-23 2011-01-27 Novartis Ag Use of azabicycloalkyl derivatives or pyrrolidine-2-one derivatives
WO2011036167A1 (en) 2009-09-22 2011-03-31 Novartis Ag Use of nicotinic acetylcholine receptor alpha 7 activators
US11096916B2 (en) 2009-09-22 2021-08-24 Novartis Ag Use of nicotinic acetylcholine receptor alpha 7 activators
US10537539B2 (en) 2009-09-22 2020-01-21 Novartis Ag Use of nicotinic acetylcholine receptor alpha 7 activators
WO2011048150A1 (en) 2009-10-20 2011-04-28 Novartis Ag Use of 1h-quinazoline-2,4-diones
WO2011161249A1 (en) 2010-06-24 2011-12-29 Novartis Ag Use of 1h-quinazoline-2,4-diones
WO2012101060A1 (en) 2011-01-27 2012-08-02 Novartis Ag Use of nicotinic acetylcholine receptor alpha 7 activators
WO2013036224A1 (en) 2011-09-07 2013-03-14 Novartis Ag Use of 1h-quinazoline- 2, 4 -diones for use in the prevention or treatment photosensitive epilepsy
WO2014111751A1 (en) 2013-01-15 2014-07-24 Novartis Ag Use of alpha 7 nicotinic receptor agonists for the treatment of narcolepsy
WO2014111837A1 (en) 2013-01-15 2014-07-24 Novartis Ag Use of alpha 7 nicotinic acetylcholine receptor agonists
US20220387410A1 (en) * 2019-11-05 2022-12-08 Claes Thulin 4-[5-[(rac)-1-[5-(3-Chlorophenyl)-3-isoxazolyl]ethoxy]-4-methyl-4H-1,2,4-triazol-3-yl]pyridine for use in prevention and/or treatment of surmenage in a mammal

Also Published As

Publication number Publication date
NO20050154L (en) 2005-01-11
CA2489730A1 (en) 2003-12-31
ZA200409908B (en) 2006-08-30
DE60320990D1 (en) 2008-06-26
UA81627C2 (en) 2008-01-25
SI1513525T1 (en) 2008-08-31
EP1513525B1 (en) 2008-05-14
ATE395059T1 (en) 2008-05-15
BR0311759A (en) 2005-03-08
RU2005101411A (en) 2005-07-10
PL372186A1 (en) 2005-07-11
RU2324484C2 (en) 2008-05-20
HK1075833A1 (en) 2005-12-30
DK1513525T3 (en) 2008-08-11
MXPA04012659A (en) 2006-05-25
PT1513525E (en) 2008-06-24
AU2003241585B2 (en) 2009-06-25
JP2006507225A (en) 2006-03-02
ES2304510T3 (en) 2008-10-16
CN1662235A (en) 2005-08-31
JP4683920B2 (en) 2011-05-18
SE0201943D0 (en) 2002-06-20
CA2489730C (en) 2011-11-22
IS7654A (en) 2005-01-19
NZ536559A (en) 2007-08-31
CY1107954T1 (en) 2013-09-04
JP2011068669A (en) 2011-04-07
EP1513525A1 (en) 2005-03-16
CN100430056C (en) 2008-11-05
IL165138A0 (en) 2005-12-18
AU2003241585A1 (en) 2004-01-06

Similar Documents

Publication Publication Date Title
EP1513525B1 (en) Use of mglur5 antagonists for the treatment of gerd
EP2289518B1 (en) Therapeutic agent for inflammatory bowel disease
WO2005077373A2 (en) Treatment of gastro-esophageal reflux disease (gerd)
KR20140030237A (en) Solid pharmaceutical composition containing benzimidazole derivative
KR20160128449A (en) Pharmaceutical preparation containing calcium antagonist/angiotensin ii receptor antagonist
US20040266861A1 (en) Use for the treatment of gastroesophageal reflux disease
US7964609B2 (en) Use of mGluR5 antagonists for the treatment of gerd
EA007952B1 (en) Use of irbesartan for the preparation of medicaments that are used to prevent or treat pulmonary hypertension
EP3900722A1 (en) Combination of finerenone and pecavaptan for the treatment and/or prevention of cardiovascular and/or renal diseases
HK1075833B (en) Use of mglur5 antagonists for the treatment of gerd
JP2004517947A (en) Use of a MGLUR5 antagonist for the treatment of pruritus
JPWO2006118212A1 (en) Preventive and therapeutic agent for pancreatitis
WO2005058361A1 (en) USE OF mGluR1 ANTAGONISTS FOR THE TREATMENT OF GERD
KR20050024351A (en) Use of MGLUR5 antagonists for the treatment of GERD
AU2002328569B9 (en) Medicinal compositions containing angiotensin II receptor antagonist
WO2005058326A1 (en) USE OF QUINAZOLINONE DERIVATIVES FOR THE INHIBITION OF TRANSIENT LOWER ESOPHAGEAL SPHINCTER RELAXATIONS (TLESRs)
TWI341729B (en)
WO2005060961A2 (en) Treatment of transient lower esophageal sphincter relaxations (tlesrs) and gastro-esophageal reflux disease (gerd)
AU740646B2 (en) Method of treating isolated systolic hypertension
CA3224505A1 (en) Low-dose naltrexol and uses thereof
Bedigian et al. I011: Angiotensin II levels are elevated at peak and trough with once daily dosing of valsartan
JP2007514788A (en) Novel Treatment for Irritable Bowel Syndrome I
Vyssoulis et al. I010: The ventricular-arterial coupling after angiotensin II receptor antagonist therapy is not renin-dependent
WO2002042765A1 (en) Remedies for digestive functional disorder and screening method

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1-2004-502010

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 2003241585

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 536559

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2003731333

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2004/09908

Country of ref document: ZA

Ref document number: 200409908

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 372186

Country of ref document: PL

Ref document number: PA/a/2004/012659

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2004515703

Country of ref document: JP

Ref document number: 2489730

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 20038141760

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 1020047020674

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 4120/DELNP/2004

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2005101411

Country of ref document: RU

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 1020047020674

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2003731333

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2006128760

Country of ref document: US

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 10517869

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 10517869

Country of ref document: US